VEGFA and gastric cancer: Meanwhile, although anti-VEGF antibody therapy failed to show effectiveness in advanced GC, a survival benefit was still obtained in second-line and third-line therapies using anti-VEGFR-2 monoclonal antibodies and small-molecule inhibitors, suggesting that some anti-angiogenic agents inducing VEGF/VEGFR signaling blockade may be effective [21, 22].